Back to news

Oruka Therapeutics Rises After Fresh Clinical Update Keeps Late-Stage Psoriasis Program on Track

Investivoq PriceTracker

Oruka Therapeutics (ORKA) is up 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to Oruka’s third-quarter update, which highlighted encouraging durability and response data for ORKA-001 and showed that key development timelines remain on track. Investors also seemed to react well to the completion of enrollment in the ORCA-SURGE Phase 2 psoriasis study for ORKA-002, which keeps another important readout lined up for early 2027.

Details:

  • Oruka said Week 16 EVERLAST-B results for ORKA-001 showed high skin-clearance rates, and management described those findings as highly consistent with prior EVERLAST-A data.
  • The company said EVERLAST-A responses continued to deepen through Week 28, reinforcing the idea that the drug may offer durable benefit with an infrequent dosing profile.
  • Management reaffirmed that 52-week EVERLAST-A data are expected in December 2026 and that the Phase 3 program for ORKA-001 remains on track to start in the first half of 2027.
  • Oruka also said ORCA-SURGE enrollment for ORKA-002 has been completed, with Week 16 psoriasis data expected in the first quarter of 2027; a same-day Buy rating was also maintained by one covering analyst, which may have added support.

    • Sources:

    Oruka Therapeutics, SEC, Benzinga

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ORKA Insider Trading Activity

    ORKA Insider Trades

    $ORKA insiders have traded $ORKA stock on the open market 97 times in the past 6 months. Of those trades, 0 have been purchases and 97 have been sales.

    Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:

    • FUNDS MANAGEMENT LLC FAIRMOUNT sold 3,553,410 shares for an estimated $300,014,406
    • LAWRENCE OTTO KLEIN (Chief Executive Officer) has made 0 purchases and 13 sales selling 129,181 shares for an estimated $11,723,377.
    • CARL DAMBKOWSKI has made 0 purchases and 5 sales selling 140,000 shares for an estimated $8,645,748.
    • PAUL T QUINLAN (General Counsel) has made 0 purchases and 17 sales selling 72,772 shares for an estimated $7,435,086.
    • ARJUN AGARWAL (Senior Vice President, Finance) has made 0 purchases and 29 sales selling 62,281 shares for an estimated $5,118,995.
    • JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 25 sales selling 43,894 shares for an estimated $3,628,154.
    • LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 7 sales selling 11,506 shares for an estimated $1,059,707.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive ORKA Data Alerts
    Get market-moving data, filings, and signals for ORKA in real time.
    Sign Up

    $ORKA Hedge Fund Activity

    We have seen 178 institutional investors add shares of $ORKA stock to their portfolio, and 86 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • CAPITAL WORLD INVESTORS added 3,401,639 shares (+inf%) to their portfolio in Q2 2026, for an estimated $323,733,983
    • RA CAPITAL MANAGEMENT, L.P. added 1,554,597 shares (+inf%) to their portfolio in Q2 2026, for an estimated $147,950,996
    • BLACKROCK, INC. added 1,463,094 shares (+41.5%) to their portfolio in Q2 2026, for an estimated $139,242,655
    • VIKING GLOBAL INVESTORS LP removed 1,163,212 shares (-43.6%) from their portfolio in Q2 2026, for an estimated $110,702,886
    • BELLEVUE GROUP AG added 1,150,182 shares (+226.9%) to their portfolio in Q2 2026, for an estimated $109,462,820
    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,103,743 shares (+inf%) to their portfolio in Q2 2026, for an estimated $105,043,221
    • FMR LLC added 1,091,222 shares (+12.0%) to their portfolio in Q3 2026, for an estimated $90,887,880

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ORKA Price Targets

    Multiple analysts have issued price targets for $ORKA recently. We have seen 2 analysts offer price targets for $ORKA in the last 6 months, with a median target of $125.0.

    Here are some recent targets:

    • Michael Yee from UBS set a target price of $130.0 on 07/01/2026
    • Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 06/23/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.